Merck & Co., Inc.
American multinational pharmaceutical company headquartered in Rahway, New Jersey; ranks fifth among biomedical companies by revenue, driven by oncology (Keytruda), vaccines (Gardasil), and animal health; does business as Merck Sharp & Dohme (MSD) outside the US and Canada.
相关临床试验
266
264 进行中
药物批准
5
批准总数
监管机构
1
监管机构数
成立时间
1891
进行中（未招募）
264
99.3%
已完成
2
0.8%
- Manufacturing accounts for roughly 80% of a pharmaceutical company's environmental footprint, making the factory floor the critical intervention point for meaningful change. - Eight leading APAC CDMOs are integrating renewable electricity, water reuse, waste recovery, green chemistry and continuous manufacturing into core production strategy rather than isolated initiatives. - The global sustainable drug manufacturing market is projected to grow from USD 105.8 billion in 2026 to USD 248.2 billion by 2036 at an 8.9% CAGR. - Scope 3 emissions, supplier engagement and internal carbon pricing are emerging as the next frontier, with WuXi AppTec reporting 82.14% of emissions from Scope 3.
- The novel hypercholesterolemia drugs market is projected to grow from USD 17.6 billion in 2026 to USD 42.8 billion by 2036, a 9.3% CAGR. - PCSK9 inhibitors are forecast to hold a 42.0% drug-class share in 2026, spanning monoclonal antibodies, inclisiran-based siRNA, and the new oral enlicitide. - Merck's Lipfendra (enlicitide) gained FDA approval in July 2026 as the first once-daily oral PCSK9 inhibitor for adults with hypercholesterolemia. - Injectable therapies lead with a 57.0% route-of-administration share, while gene-editing programs from Verve, CRISPR Therapeutics, and Eli Lilly advance toward one-time treatment.
- The Southeast Asia oncology drug access market is projected to grow from USD 3.19 billion in 2026 to USD 4.41 billion by 2031, at a CAGR of 6.7%. - Rising cancer burden, particularly breast, lung, colorectal, liver, and cervical cancers, alongside hematologic malignancies, is fueling demand for affordable oncology therapies. - Biosimilars, generics, patient assistance programs, and precision oncology advances are reshaping treatment accessibility across the region. - Key challenges include high out-of-pocket costs, fragmented regulations, and rural infrastructure limitations, though healthcare reforms present growth opportunities.
- The Association for the Accreditation of Human Research Protection Programs (AAHRPP) has awarded full accreditation to five new entities, including Merck & Co., Inc. and MedStar Health Research Institute. - An additional 21 organizations earned reaccreditation, joining more than 600 entities worldwide committed to AAHRPP's ethical research standards. - AAHRPP President and CEO Elyse I. Summers emphasized that each accreditation strengthens research protections and helps restore public trust in science. - The Uniformed Services University of the Health Sciences, a U.S. government institution, was recognized for sending a "deliberate, powerful message" about its dedication to safe, ethical research.
- Long-term follow-up of KEYNOTE-966 shows the addition of pembrolizumab to gemcitabine and cisplatin maintained a clinically meaningful overall survival benefit with no new safety signals. - Overall grade 3 or 4 adverse event rates were comparable between treatment arms, with cytopenias as the most common events attributable to the chemotherapy backbone. - Immune-mediated adverse events and infusion reactions occurred more often with pembrolizumab, most commonly hypothyroidism and pneumonitis. - The data align with TOPAZ-1 findings, where grade 3 or 4 adverse events were similar between arms and immune-mediated events were generally manageable.
- Merck's anti-TL1A antibody tulisokibart met its primary and key secondary endpoints in the Phase 3 ATLAS-UC induction study for moderately to severely active ulcerative colitis. - The positive result strengthens Merck's immunology pipeline and offers a potential new growth driver as the company seeks to diversify revenue beyond Keytruda. - Merck also recently secured FDA expansion approvals for KEYTRUDA with WELIREG in kidney cancer and for CAPVAXIVE in higher-risk children and adolescents. - The tulisokibart data adds to Merck's recent pipeline momentum, reinforcing confidence in a potentially important new immunology asset.
- Immuneering Corporation names Andrew Gengos, former CFO of Terns Pharmaceuticals, as its new Chief Financial Officer effective July 16, 2026. - Gengos brings over 25 years of biotech leadership experience, including roles at Amgen, Athira Pharma, and Cyteir Therapeutics, and was at Terns during its $6.7 billion acquisition by Merck. - He will oversee financial strategy and corporate development as the company advances atebimetinib, its lead Deep Cyclic Inhibitor, through the Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer. - Atebimetinib is an oral, once-daily MEK inhibitor designed to improve overall survival in RAS, RAF, and other MAPK-driven cancers through durable tumor shrinkage, cachexia counteraction, and minimized side effects.
- The global antibody therapeutics market was valued at US$ 266.9 billion in 2024 and is projected to reach US$ 737.6 billion by 2034, growing at a CAGR of 10.7%. - Monoclonal antibodies dominated the market with a 62.7% share in 2024, while the oncology segment accounted for 58.4% of total revenue. - North America led the global market with a 41.8% share in 2024, while Asia Pacific is expected to register the fastest growth during the forecast period. - Advancements in AI-driven antibody discovery, bispecific antibodies, and antibody-drug conjugates are expanding therapeutic applications across cancer, autoimmune, and neurological disorders.
- Merck Animal Health has signed a definitive agreement to acquire TARGAN, a privately held biodevice innovator for the poultry industry, with closing expected in Q3 2026. - The acquisition brings WingScan™, an automated chick gender identification system using vision technology and proprietary algorithms capable of processing up to 160,000 chicks per hour. - TARGAN's portfolio also includes high-speed precision ocular spray technology for administering respiratory and coccidiosis vaccines to day-old chicks. - Merck Animal Health has been an investor in TARGAN since 2017 and was one of the company's largest shareholders prior to the acquisition.
- Therini Bio has dosed the first patients in a Phase 1b trial evaluating THN391, a potential first-in-class humanized monoclonal antibody targeting fibrin-driven inflammation in diabetic macular edema. - THN391 demonstrated efficacy comparable to VEGF antagonists in preclinical models for containing neovascular leakage, according to research published in the Journal of Neuroinflammation. - The company is also advancing THN622, a bispecific antibody combining anti-fibrin and anti-VEGF mechanisms that could potentially become a new standard of care for neurodegenerative ocular diseases. - Initial data from the Phase 1b multiple ascending dose study is expected in Q4 2026, with the trial designed to assess safety and preliminary efficacy across three dose cohorts.
